E2F1 transcription factor mediates a link between fat and islets to promote β cell proliferation in response to acute insulin resistance

Jun Shirakawa,Yu Togashi,Giorgio Basile,Tomoko Okuyama,Ryota Inoue,Megan Fernandez,Mayu Kyohara,Dario F De Jesus,Nozomi Goto,Wei Zhang,Takahiro Tsuno,Tatsuya Kin,Hui Pan,Jonathan M Dreyfuss,A M James Shapiro,Peng Yi,Yasuo Terauchi,Rohit N Kulkarni
DOI: https://doi.org/10.1016/j.celrep.2022.111436
2022-10-04
Abstract:Prevention or amelioration of declining β cell mass is a potential strategy to cure diabetes. Here, we report the pathways utilized by β cells to robustly replicate in response to acute insulin resistance induced by S961, a pharmacological insulin receptor antagonist. Interestingly, pathways that include CENP-A and the transcription factor E2F1 that are independent of insulin signaling and its substrates appeared to mediate S961-induced β cell multiplication. Consistently, pharmacological inhibition of E2F1 blocks β-cell proliferation in S961-injected mice. Serum from S961-treated mice recapitulates replication of β cells in mouse and human islets in an E2F1-dependent manner. Co-culture of islets with adipocytes isolated from S961-treated mice enables β cells to duplicate, while E2F1 inhibition limits their growth even in the presence of adipocytes. These data suggest insulin resistance-induced proliferative signals from adipocytes activate E2F1, a potential therapeutic target, to promote β cell compensation.
What problem does this paper attempt to address?